KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2024 · Molecular Cancer Therapeutics · 15 citations
https://doi.org/10.1158/1535-7163.mct-24-0306
M
Michele Mayo
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
97
Papers
1.5K
Citations
18
h-index
21
i10-index
Michele Mayo is an academic researcher. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Cancer-related Molecular Pathways & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 18, co-authored 83 publications.
ORCID: 0009-0005-0359-7900Papers by this author
worksSupplemental Figure 2 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025 · 0 citations
https://doi.org/10.1158/1535-7163.28713654
Supplemental Table 4 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025 · 0 citations
https://doi.org/10.1158/1535-7163.28713624
Supplemental Figure 7 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025 · 0 citations
https://doi.org/10.1158/1535-7163.28713636
Supplemental Figure 5 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025 · 0 citations
https://doi.org/10.1158/1535-7163.28713645
Supplemental Table 5 from KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors
2025 · 0 citations
https://doi.org/10.1158/1535-7163.28713621
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat